Hepion Pharmaceuticals, Inc. (HEPA)
OTCMKTS
· Delayed Price · Currency is USD
0.0541
-0.0159 (-22.71%)
At close: Apr 29, 2026
Hepion Pharmaceuticals Employees
Hepion Pharmaceuticals had 2 employees as of December 31, 2025. The number of employees decreased by 20 or -90.91% compared to the previous year.
Employees
2
Change
-20
Growth
-90.91%
Revenue / Employee
n/a
Profits / Employee
-$4,138,925
Market Cap
1.58M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Emmaus Life Sciences | 33 |
| Eloxx Pharmaceuticals | 10 |
| Abpro Holdings | 3 |
| Iterum Therapeutics | 9 |
| Bio-Path Holdings | 1 |
| Altamira Therapeutics | 11 |
Hepion Pharmaceuticals News
- 2 months ago - Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma - GlobeNewsWire
- 11 months ago - Hepion Pharmaceuticals Successfully Completes Application to the OTCQB - GlobeNewsWire
- 1 year ago - Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq - GlobeNewsWire
- 1 year ago - Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC - GlobeNewsWire
- 1 year ago - Hepion Pharmaceuticals Announces Reverse Stock Split - GlobeNewsWire
- 1 year ago - Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd. - GlobeNewsWire
- 1 year ago - Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson's Disease Study Group - GlobeNewsWire
- 1 year ago - Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B - GlobeNewsWire